八旬与非八旬重症肢体缺血患者腔内血运重建后的结局
CRITISCH多中心前瞻性注册研究纳入642例接受腔内技术治疗的CLI患者,按年龄分为<80岁组(n=421)和≥80岁组(n=221)。两组1年无截肢生存率相当(75% vs 77%,p=0.340),但八旬组免于MALE(62% vs 72%,HR 1.45,95%CI 1.09–1.93,p=0.016)和肢体挽救率(90% vs 95%,HR 2.16,95%CI 1.27–3.69,p=0.01)更优。
要点
- 八旬CLI患者腔内治疗后1年无截肢生存率与年轻患者相当(75% vs 77%,p=0.340)。
- 八旬组免于MALE率(72% vs 62%)和肢体挽救率(95% vs 90%)显著高于年轻组。
- 院内死亡(1% vs 2%,p=0.204)和大截肢(4% vs 2%,p=0.169)两组无显著差异。
核心结论
- 八旬CLI患者接受腔内血运重建的早期和1年无截肢生存率与年轻患者相当,肢体挽救率和免于MALE率甚至更高。
研究设计与样本
- CRITISCH为多中心前瞻性注册研究(NCT01877252),共纳入642例接受腔内技术治疗的CLI患者。
- 按年龄分为<80岁组(n=421,平均69岁,292例男性)和≥80岁组(n=221,平均85岁,113例男性)。
- 两组Rutherford 4–6级分布相似,但<80岁组男性、吸烟者、糖尿病患者及透析患者更多。
主要发现
- 院内死亡率<80岁组1%、≥80岁组2%(p=0.204),大截肢率分别为4%和2%(p=0.169)。
- 1年无截肢生存率<80岁组75%、≥80岁组77%(p=0.340)。
- 免于MALE率<80岁组62%、≥80岁组72%(HR 1.45,95%CI 1.09–1.93,p=0.016)。
- 肢体挽救率<80岁组90%、≥80岁组95%(HR 2.16,95%CI 1.27–3.69,p=0.01)。
临床怎么用
- 对八旬CLI患者,腔内血运重建可作为可行的血运重建策略,其早期及1年无截肢生存与年轻患者相当。
- 八旬患者肢体挽救率和免于MALE率更优,年龄本身不应成为拒绝腔内治疗的依据。
局限性
- 原文摘要未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the outcome and periprocedural risk of endovascular revascularization in octogenarians with critical limb ischemia (CLI) compared with their younger counterparts. METHODS: The multicenter, prospective registry for First-line Treatments in Patients With Critical Limb Ischemia (CRITISCH) enrolled 642 patients treated with endovascular techniques ( ClinicalTrials.gov identifier NCT01877252). The patients were dichotomized according to age <80 years (n=421; mean age 69 years, 292 men; group 1) or ≥80 years (n=221; mean age 85 years, 113 men; group 2). The groups had similar distributions in Rutherford categories 4 to 6, but group 1 had more men, smokers, diabetics, and patients on dialysis. The primary composite endpoint of the study was amputation and/or death. Key secondary endpoints were in-hospital mortality and major amputation, as well as major adverse limb events (MALE; any reintervention or major amputation involving the index limb) at 1 year. RESULTS: The in-hospital mortality was 1% in group 1 and 2% in group 2 (p=0.204) and the major amputation rates were 4% and 2% (p=0.169), respectively. Amputation-free survival at 1 year was 75% in group 1 and 77% in group 2 (p=0.340), whereas freedom from MALE was significantly different between the groups [62% group 1 vs 72% group 2; hazard ratio (HR) 1.45, 95% confidence interval (CI) 1.09 to 1.93, p=0.016). Limb salvage was 90% in group 1 and 95% in group 2 (HR 2.16, 95% CI 1.27 to 3.69, p=0.01). CONCLUSION: Octogenarians with CLI treated by endovascular means showed comparable early and 1-year amputation-free survival rates vs their younger counterparts, and limb salvage and freedom from MALE rates were even higher in octogenarians. APPENDIX: The CRITISCH collaborators are Farzin Adili, MD (Darmstadt), Kai Balzer, MD (Bonn), Arend Billing, MD (Offenbach), Dittmar Böckler, MD (Heidelberg), Daniel Brixner, MD (Offenbach), Sebastian E. Debus, MD (Hamburg), Hans-Henning Eckstein, MD (München), Hans-Joachim Florek, MD (Freital), Asimakis Gkremoutis, MD (Frankfurt), Reinhardt Grundmann, MD (Bad Krozingen), Thomas Hupp, MD (Stuttgart), Se-Won Hwang, MD (Muenster), Tobias Keck, MD (Lübeck), Wojciech, Klonek, MD (Cloppenburg), Werner Lang, MD (Erlangen), Björn May (Freital), Alexander Meyer, MD (Erlangen), Bernhard Mühling, MD (Biberach), Alexander Oberhuber, MD (Düsseldorf), Holger Reinecke, MD (Münster), Christian Reinhold, MD (Mönchengladbach), Ralf-Gerhard Ritter, MD (Bielefeld), Hubert Schelzig, MD (Düsseldorf), Christian Schlensack, MD (Tübingen), Thomas Schmitz-Rixen, MD (Frankfurt), Karl-Ludwig Schulte, MD (Berlin), Matthias Spohn, MD (Bamberg), Konstantinos Stavroulakis, MD (Münster), Martin Storck, MD (Karlsruhe), Matthias Trede, MD (Bremen), Barbara Weis-Müller, MD (Mönchengladbach), Heiner Wenk (Bremen), Thomas Zeller, MD (Bad Krozingen), Sven Zhorzel, MD (Munich), and Alexander Zimmermann, MD (Munich).
引用
- Uhl C, Steinbauer M, Torsello G, et al. Outcomes After Endovascular Revascularization in Octogenarians and Non-Octogenarians With Critical Limb Ischemia. J Endovasc Ther. 2017. PMID: 28578624. doi:10.1177/1526602817711424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。